Table 3.
Prevalence of metabolic syndrome (MetS) and its criteria among subjects
| All | Male | Female | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Inpatients | Outpatients | P value | Inpatients | Outpatients | P value | Inpatients | Outpatients | P value | |
| MetS prevalence: | |||||||||
| ATP III-A | 15.8 | 48.1 | < 0.001 | 14.1 | 55.8 | < 0.001 | 17.3 | 40.6 | < 0.001 |
| IDF | 14.7 | 44.1 | < 0.001 | 11.9 | 48.6 | < 0.001 | 17.1 | 39.4 | < 0.001 |
| JASSO | 9.1 | 33.2 | < 0.001 | 13.6 | 45.8 | < 0.001 | 5.1 | 20.2 | < 0.001 |
| MetS criteria prevalence: | |||||||||
| Waist circumference | |||||||||
| Male ≥ 90 cm, female ≥ 80 cm | 46.2 | 64.2 | < 0.001 | 27.8 | 61.7 | < 0.001 | 62.4 | 66.8 | NS |
| Male ≥ 85 cm, female ≥ 90 cm | 34.9 | 59.0 | < 0.001 | 42.3 | 73.8 | < 0.001 | 28.4 | 43.8 | < 0.001 |
| BP (≥ 130/85 mmHg) | 30.7 | 46.7 | < 0.001 | 37.2 | 55.5 | < 0.001 | 25.1 | 37.5 | < 0.01 |
| HDL (male < 40 mg/dl, female < 50 mg/dl) | 25.5 | 31.8 | < 0.05 | 22.7 | 28.9 | NS | 28.0 | 34.8 | NS |
| Triglyceride (≥ 150 mg/dl) | 11.2 | 40.6 | < 0.001 | 13.2 | 50.2 | < 0.001 | 9.4 | 31.0 | < 0.001 |
| HDL (< 40 mg/dl) and TG (≥ 150 mg/dl) | 20.8 | 46.1 | < 0.001 | 28.2 | 58.1 | < 0.001 | 14.4 | 34.0 | < 0.001 |
| Glucose (≥ 100 mg/dl) | 17.5 | 50.9 | < 0.001 | 16.6 | 56.0 | < 0.001 | 18.4 | 45.5 | < 0.001 |
| Glucose (≥ 110 mg/dl) | 9.5 | 35.3 | < 0.001 | 9.9 | 36.8 | < 0.001 | 9.2 | 33.7 | < 0.001 |
All prevalences are expressed as a percentage (%) and were analyzed using the χ2 test comparing the reference group and the schizophrenic patients.
ATP III-A = Adapted National Cholesterol Education Program Adult Treatment Panel; BP = blood pressure; IDF = International Diabetes Federation; JASSO = Japan Society for the Study of Obesity; HDL = high-density lipoprotein; NS = not significant.